Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis
Main finding · CDAI MCID achievementResult — go to the resultOdds ratio 0.69 95% CI 0.56–0.86Authors' conclusion
Metabolic syndrome is associated with lower response rates with the initiation of an advanced therapy in RA, with similar effects for both TNFi and non-TNFi agents.
Study context
- Population
- Participants with rheumatoid arthritis (RA) initiating tumor necrosis factor inhibitor (TNFi) or non-TNFi biologic therapies, CERTAIN cohort within the CorEvitas registryadipokine subsample n = 200
- Participants
- 2,368 participants
- Exposure
- Metabolic syndrome vs no metabolic syndrome
- Metabolic syndromen = 687
- Outcome
- Achievement of a change as large as the MCID for the Clinical Disease Activity Index (CDAI)
- Follow-up
- 6 months
Methodological detailsregistry-based (CERTAIN cohort within CorEvitas registry)
- Registry-based (CERTAIN cohort within CorEvitas registry)
Main finding
CDAI MCID achievement
Odds ratio
0.69
95% CI 0.56–0.86
P = 0.001
Metabolic syndromevs No metabolic syndrome
OR 0.69 (95% CI 0.56–0.86); P = 0.001
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| CDAI MCID achievement by therapy (subgroup) · 6 monthsMetabolic syndromevs No metabolic syndromeTNFi | 0.65 (0.49–0.87) | P = 0.003 | |
| CDAI MCID achievement by therapy (subgroup) · 6 monthsMetabolic syndromevs No metabolic syndromenon-TNF therapies | 0.76 (0.55–1.04) | P = 0.08 [P for interaction = 0.49] | |
| 0.512Odds ratio (log scale) |
Adipokines and minimal clinically important difference (MCID) achievement
- Adipokines were not associated with MCID achievement
Original publication
Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis. Arthritis Rheumatol. Published 4 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →